Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Nov. 10 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended September 30, 2008.

"The third quarter represented another quarter of significant achievement and progress and was capped with the signing of our partnering agreement with Pfizer for Dimebon. This collaboration not only gives us access to a world-class partner capable of maximizing global commercialization, but also provides significant funding allowing us to invest in all of our clinical programs and actively pursue other drug candidates," said David Hung, M.D., president and chief executive officer of Medivation. "We are working with Pfizer on an extensive program to support a broad label for Dimebon in Alzheimer's disease beyond our original plan to pursue the treatment of mild-to-moderate Alzheimer's, and to achieve comprehensive and expeditious regulatory submissions and market acceptance. Accordingly, together we intend to expand development of Dimebon to include new Phase 3 trials in addition to the CONNECTION study. We expect to begin the new trials in 2009 and to file a New Drug Application (NDA) for a broader Alzheimer's disease label in 2011."

Corporate Update

Dimebon: Drug candidate to treat Alzheimer's and Huntington's diseases

-- Entered into an agreement with Pfizer Inc. to jointly develop and

commercialize Dimebon for the treatment of Alzheimer's and Huntington's

diseases. Under the terms of the agreement, Medivation has received an

up-front cash payment of $225 million and is eligible to receive

payments of up to $500 million upon the attainment of development and

regulatory milestones, plus additional undisclosed commercial milestone

payments.

-- Enrollment in CONNECTION, our confirmatory Phase 3 trial in

mild-to-moderate Alzheimer's disease, continues on track. All 30 of

our U.S. sites have been opened, and we expect the majority of our

ex-U.S. sites to be opened by the end of November. We expect to

complete enrollment of this trial in 2009.

-- Completed a randomized, double-blind safety and tolerability study of

combination therapy with Dimebon and donepezil (Aricept(R)) in patients

with Alzheimer's disease, which found the combination to be well

tolerated with no serious adverse events.

-- Plan to initiate new Phase 3 studies in 2009 to seek further

differentiation of Dimebon to include moderate-to-severe Alzheimer's

disease, adjunctive use with cholinesterase inhibitors, and

twelve-month efficacy.

-- Received a Corporate Achievement Award from the Huntington's Disease

Society of America (HDSA) for exemplifying leadership in the fight

against Huntington's disease and other neurodegenerative diseases.

-- Plan to initiate the next Huntington's disease efficacy study in 2009.

MDV3100: Drug candidate to treat castration-resistant prostate cancer

-- Presented data at the 20th EORTC-NCI-AACR Symposium on "Molecular

Targets and Cancer Therapeutics" from an ongoing open-label,

dose-escalation, U.S.-based Phase 1-2 clinical trial in prostate cancer

patients who have failed standard hormonal therapies. Results showed

encouraging and durable anti-tumor activity in the three expanded dose

groups tested thus far, as measured by prostate specific antigen (PSA)

declines, radiographic findings, circulating tumor cell (CTC) changes,

and time on treatment. MDV3100 has been generally well tolerated, with

no reports of serious adverse events deemed related to the drug.

-- Approximately 120 patients have been enrolled in the trial with

enrollment completed at doses up to 360 mg/day. A total of 73 patients

in the three lowest expanded dose groups (60, 150, and 240 mg/day) have

been followed for more than 24 weeks. Of these 73 patients, 31

patients (42 percent) have received MDV3100 for greater than 24 weeks.

Dose escalation in the trial is continuing; the 360 mg/day expansion

group is completely enrolled, dose escalation is in progress at 480

mg/day, and initial dosing at 600 mg/day has started. Thus far a

maximum tolerated dose (MTD) has not been reached.

-- Medivation expects to seek FDA agreement to begin a pivotal Phase 3

registration study in castration-resistant prostate cancer patients in

2009.

Third Quarter 2008 Financial Results

Medivation reported a net loss for the quarter ended September 30, 2008 of $20.5 million, or $0.68 per share, compared with a net loss of $9.4 million, or $0.34 per share, for the same period in 2007. For the nine months ended September 30, 2008, the net loss was $54.5 million, or $1.86 per share, compared with a net loss of $22.2 million, or $0.80 per share, for the same period in 2007.

Total operating expenses for the nine months ended September 30, 2008 were $20.6 million, compared with $9.8 million for the same period in 2007. The increase in operating expenses for the third quarter of 2008 compared with the same period in 2007 is primarily due to increased development costs associated with Dimebon and MDV3100.

For the nine months ended September 30, 2008, total operating expenses were $55.3 million, compared with total operating expenses of $23.7 million for the same period in 2007. These figures include non-cash stock-based compensation expense of $6.4 million in the nine months ended September 30, 2008 compared with $4.3 million for the same period in 2007. Pfizer will fund 60 percent of U.S. Dimebon-related development expenses incurred on or after October 21, 2008, the closing date of our collaboration agreement, and 100 percent of ex-U.S. Dimebon-related development expenses. Thus, we expect that Dimebon-related operating expenses after cost sharing payments from Pfizer will decrease in the fourth quarter of 2008 compared with the third quarter. We intend to provide full-year 2009 financial guidance in the first quarter of 2009.

Cash and cash equivalents at September 30, 2008 totaled $20.4 million, compared with $43.3 million at December 31, 2007. On October 27, 2008, Medivation received its $225 million up-front payment from Pfizer pursuant to the Dimebon collaboration agreement. Even after taking into account the expanded Dimebon development being undertaken with Pfizer, the upfront payment and development milestone payments Medivation is eligible to receive under the Pfizer agreement significantly exceed the Company's share of presently budgeted development and pre-launch commercialization costs for Dimebon.

Conference Call Information

To participate in today's live call beginning at 4:30 p.m. Eastern Time by telephone, please call 877-340-7912 from the U.S. or +719-325-4872 internationally. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans and milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q filed today with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

~financial statements to follow~

MEDIVATION, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Period from

Inception

Three Months Ended Nine Months Ended (September 4, 2003)

September 30, September 30, to

2008 2007 2008 2007 September 30, 2008

Operating

expenses:

Research

and

develop-

ment $15,514 $6,797 $41,728 $16,306 $84,067

General

and

admin-

istrative 5,122 3,026 13,532 7,383 32,694

Total

operating

expenses 20,636 9,823 55,260 23,689 116,761

Loss from

operations (20,636) (9,823) (55,260) (23,689) (116,761)

Other income

(expense):

Interest

income,

net 170 460 735 1,522 3,674

Other

income

(expense),

net 10 - (4) (3) (1,642)

Total

other

income

(expense) 180 460 731 1,519 2,032

Net loss $(20,456) $(9,363) $(54,529) $(22,170) $(114,729)

Basic and

diluted net

loss per

share $(0.68) $(0.34) $(1.86) $(0.80)

Weighted

average

common

shares

used

in the

calculation

of basic

and

diluted

net loss

per share 30,022 27,797 29,273 27,776

MEDIVATION, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(unaudited)

September 30, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $20,374 $43,258

Prepaid expenses and other current assets 1,683 991

Total current assets 22,057 44,249

Property and equipment, net 728 689

Intellectual property, net 55 58

Other non-current assets 1,195 600

Total assets $24,035 $45,596

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $6,203 $1,747

Accrued expenses 8,793 2,218

Other current liabilities 87 70

Total current liabilities 15,083 4,035

Other non-current liabilities 426 492

Series A redeemable preferred stock 11 11

Total liabilities 15,520 4,538

Stockholders' equity:

Preferred stock, $0.01 par value per share;

1,000,000 shares authorized; no shares

issued and outstanding - -

Common stock, $0.01 par value per share;

50,000,000 shares authorized; issued and

outstanding 30,079,390 shares at 301 288

September 30, 2008 and 28,837,290 at

December 31, 2007

Additional paid-in capital 122,943 100,970

Deficit accumulated during the development

stage (114,729) (60,200)

Total stockholders' equity 8,515 41,058

Total liabilities and stockholders' equity $24,035 $45,596


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), ... Eugene Seymour , MD, MPH, will present information about the company,s ... Hotel in New York City . ... the Windsor Room at 5:30PM EST. Registered attendees can request a ... York City . --> New York ...
(Date:2/8/2016)... , Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website ... pharmacy resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit the ... ... ... "The goal was to ...
(Date:2/6/2016)... ... 06, 2016 , ... The Center for Excellence in Education (CEE) will sponsor ... on Wednesday February 10, 2016. This Bite of Science session, hosted by the ... at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. ...
(Date:2/5/2016)... -- ATCC, the premier global biological materials resource and ... life science researchers that are working to address the ... CDC website . --> CDC website ... single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, ... Viruses. Zika virus is transmitted to humans primarily through ...
Breaking Biology Technology:
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon ... from the U.S. Army Research Office and the ... range and sensitivity of the company,s Snapshot ... Accounting Mission and, more generally, defense-related DNA forensics. ... phenotyping capabilities (predicting appearance and ancestry from DNA ...
Breaking Biology News(10 mins):